P105 Does asthma control change when patients transition to home administration of mepolizumab?
Sign Up to like & getrecommendations! Published in 2021 at "Thorax"
DOI: 10.1136/thorax-2020-btsabstracts.250
Abstract: Introduction: Mepolizumab is a biologic agent targeting interleukin (IL)-5 which is currently licensed as add-on therapy for severe eosinophilic asthmatic (SEA) It is usually administered in a hospital setting but with the option of homecare… read more here.
Keywords: homecare; home; asthma control; acq6 ... See more keywords